STOCK TITAN

Purple Biotech Q3 2026 net loss narrows to $981K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Purple Biotech Ltd. (PPBT) reported third-quarter 2026 operating loss of $1,099,000, compared with $1,367,000 a year earlier, and net loss of $981,000, compared with $1,305,000. Research and development expenses were $364,000 versus $587,000, and general and administrative expenses were $735,000 versus $780,000. For the first nine months, operating loss increased to $4,650,000 from $4,013,000, while operating activities used $6,417,000 in cash, compared with $4,589,000.

Cash, cash equivalents and short-term deposits totaled $5.1 million as of September 30, 2026; management estimates these funds are expected to provide a cash runway through late 2027 under the current operating plan. Purple Biotech plans to submit an Investigational New Drug application for lead candidate IM1240 during 2027. IM1240 data from treatment-resistant human tumor models are scheduled for presentation on November 20, 2026, at an EORTC-NCI-AACR symposium. The company also reported that a U.S. patent covering CAPTN-3 antibody constructs and methods of use was granted after a September 2026 notice of allowance.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointThird-quarter operating loss narrowed to $1,099,000 from $1,367,000.
  • Moderate pointThird-quarter net loss narrowed to $981,000 from $1,305,000.

Negative

  • Moderate pointNine-month operating loss increased to $4,650,000 from $4,013,000.
  • Moderate pointOperating cash use rose to $6,417,000 from $4,589,000.
Research and development expenses $364,000; $587,000 Three months ended September 30, 2026 and 2025, respectively
General and administrative expenses $735,000; $780,000 Three months ended September 30, 2026 and 2025, respectively
Operating loss $1,099,000; $1,367,000 Three months ended September 30, 2026 and 2025, respectively
Net loss $981,000; $1,305,000 Three months ended September 30, 2026 and 2025, respectively
Operating loss $4,650,000; $4,013,000 Nine months ended September 30, 2026 and 2025, respectively
Net cash used in operating activities $6,417,000; $4,589,000 Nine months ended September 30, 2026 and 2025, respectively
Cash, cash equivalents and short-term deposits $5.1 million As of September 30, 2026
Investigational New Drug (IND) application regulatory
"Investigational New Drug (IND) application submission planned during 2027"
An investigational new drug (IND) application is a formal request submitted to a drug regulator asking permission to begin testing a new medicine in people. It compiles lab results, manufacturing details and proposed human trial plans so regulators can judge safety before human studies start; for investors, an accepted IND is a key milestone that opens the clinical development pathway and can materially change a company’s risk profile and potential value, like getting a license to road-test a prototype.
tri-specific antibody medical
"IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A)"
A tri-specific antibody is a lab-engineered immune protein designed to bind three different targets at once, such as two disease markers and an immune-cell trigger. Think of it as a three-pronged tool that brings multiple parts of the body’s defense system together or blocks several disease signals simultaneously. Investors care because this approach can produce more potent or versatile treatments with higher potential returns, but it also involves greater scientific complexity, development risk, and regulatory scrutiny.
tumor microenvironment medical
"confine that activity to the tumor microenvironment"
The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.
pharmacokinetic medical
"pharmacokinetic and safety evaluation of CAPTN-3's conditional CD3 masking approach"
Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.
conditional CD3 masking approach medical
"safety evaluation of CAPTN-3's conditional CD3 masking approach"
Adjusted net loss financial
"Adjusted net loss excludes non-cash share-based compensation expenses"
Adjusted net loss is the company’s reported net loss after removing one-time, non-cash, or unusual items that management says obscure underlying results, such as restructuring charges, asset write-downs, or stock-based pay. Investors use it to focus on the business’s core profitability — like smoothing out potholes to judge road quality — but should be cautious because choices about what to exclude can make performance look better than it really is.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was PPBT's third-quarter 2026 net loss?

Purple Biotech reported a net loss of $981,000 for the three months ended September 30, 2026, compared with $1,305,000 for the same period in 2025.

How long does PPBT expect its cash runway to last?

Purple Biotech reported $5.1 million in cash, cash equivalents and short-term deposits as of September 30, 2026. Based on current management estimates and its current operating plan, these funds are expected to provide a cash runway through late 2027.

What does PPBT's adjusted net loss exclude?

Adjusted net loss excludes non-cash share-based compensation expenses and finance income or expenses resulting from changes in the fair value of outstanding warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of November 2026

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

Purple Biotech Ltd.

On November 17, 2026, Purple Biotech Ltd. (the “Registrant”) issued a press release “Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update”, which is attached hereto as Exhibit 99.1.

Exhibit  
99.1 Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update

Incorporation by Reference

This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107), the Registrant’s Registration Statement on Form F-3, originally filed with the Securities and Exchange Commission on December 8, 2022, as amended by Form F-3/A filed with the Securities and Exchange Commission on May 17, 2023 (Registration file number 333-268710), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), and the Registrant’s Registration Statement on Form F-3, originally filed with the Securities and Exchange Commission on May 20, 2026, as amended by Form F-3/A filed with the Securities and Exchange Commission on November 6, 2026 (Registration file number 333-296088), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

November 17, 2026PURPLE BIOTECH LTD.
   
 By:/s/ Shai Lankry
  Shai Lankry
  Chief Financial Officer

Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update

 

IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A): Investigational New Drug (IND) application submission planned during 2027, followed by a first-in-human study

IM1240 data to be presented in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026

REHOVOT, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced financial results for the three and nine months ended September 30, 2026, and provided an update on recent business progress.

“Purple Biotech today has a focused set of assets: the CAPTN-3 platform, its lead candidate IM1240, and a second candidate, IM1305. That foundation was built under Gil Efron as Chief Executive Officer,” said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. “My first priority is to bring IM1240 into a first-in-human study. What we believe sets CAPTN-3 apart is that its antibodies are designed to engage both T cells and NK cells against the tumor and to confine that activity to the tumor microenvironment. Many patients with advanced solid tumors do not respond to today’s immunotherapies, or relapse after an initial response. Those are the patients we are working for.”

“Alongside our preparation of an IND application for IM1240, we continue to advance additional work on the platform. IM1240 data in treatment-resistant human tumor models will be presented this week in a plenary session at the EORTC-NCI-AACR Symposium. Separately, we plan to report new preclinical data on IM1305, our second candidate, in the near term,” Mr. Israel added. “As we previously reported, we are also bringing artificial intelligence into our antibody development. In our collaboration with Converge Bio, we are applying generative artificial intelligence to the design and optimization of our tri-specific antibodies, and we expect to provide an update on that work shortly. We believe artificial intelligence has the potential to make significant parts of drug development more efficient, and we intend to extend its use across the Company, with attention to data security and privacy.”

Business Update:

IM1240 abstract selected for a plenary oral presentation at the 38th EORTC-NCI-AACR Symposium

 

  • Data evaluating IM1240 in treatment-resistant human tumor models, including its multi-arm mechanism of action and the contribution of NKG2A engagement, as well as the pharmacokinetic and safety evaluation of CAPTN-3's conditional CD3 masking approach, will be presented by Amir Horowitz, Ph.D., of the Icahn School of Medicine at Mount Sinai, in Plenary Session 7: Proffered Papers on Friday, November 20, 2026, at 15:00 CET (Abstract ENA26-0137).

 

U.S. patent granted for the CAPTN-3 platform

 

  • In September 2026, we received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering tri-specific antibody constructs and methods of use, and the patent was subsequently granted. The patent further strengthens our intellectual property portfolio and supports the development and partnering potential of the CAPTN-3 platform.

 

 

Financial Results for the Three Months Ended September 30, 2026

Research and Development Expenses were $0.4 million for the three months ended September 30, 2026, compared to $0.6 million for the same period in 2025, representing a decrease of $0.2 million. The decrease was primarily attributable to lower Chemistry, Manufacturing and Controls (CMC) and patent expenses.

General and Administrative Expenses were $0.7 million for the three months ended September 30, 2026, compared to $0.8 million for the corresponding period in 2025. The decrease was mainly due to lower consulting and non-cash bonus expenses.

Operating Loss was $1.1 million for the three months ended September 30, 2026, compared to $1.4 million for the corresponding period in 2025, representing a decrease of $0.3 million. The decrease was primarily attributable to lower research and development and general and administrative expenses.

Adjusted Operating Loss (as reconciled below) was $1.0 million for the three months ended September 30, 2026, compared to $1.3 million for the corresponding period in 2025.

Finance Income, Net was $0.1 million for the three months ended September 30, 2026, and for the corresponding period in 2025.

Net Loss was $1.0 million for the three months ended September 30, 2026, compared to $1.3 million for the corresponding period in 2025. The decrease was primarily attributable to lower operating expenses, and, to a lesser extent, to higher non-cash finance income resulting from changes in the fair value of outstanding warrants.

Adjusted Net Loss (as reconciled below) was $1.1 million for the three months ended September 30, 2026, compared to $1.2 million for the same period in 2025. Adjusted net loss excludes non-cash share-based compensation expenses and finance income or expenses resulting from changes in the fair value of outstanding warrants.

As of September 30, 2026, we had cash, cash equivalents and short-term deposits of $5.1 million, which, based on current management estimates and our current operating plan, are expected to provide us with a cash runway through late-2027.

 

Non-IFRS Financial Measures

 

This press release includes information about certain financial measures that are not prepared in accordance with International Financial Reporting Standards ("IFRS"), including adjusted operating loss and adjusted net loss. These non-IFRS measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similar measures presented by other companies. Adjusted operating loss and adjusted net loss adjust for non-cash share-based compensation expenses, and adjusted net loss also adjusts for finance income or expenses resulting from changes in the fair value of outstanding warrants. The Company's management and board of directors utilize these non-IFRS financial measures to evaluate its performance. The Company provides these non-IFRS measures of its performance to investors because management believes that these non-IFRS financial measures, when viewed with its results under IFRS and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, these non-IFRS measures are not measures of financial performance under IFRS and, accordingly, should not be considered in isolation or as alternatives to IFRS measures as indicators of operating performance. Further, these non-IFRS measures should not be considered measures of the Company's liquidity. A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

 

About Purple Biotech

 

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company is focused on advancing CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Capping technology is designed to confine immune activation to the tumor microenvironment and, based on preclinical data, to expand the therapeutic window compared to conventional T-cell engagers. The platform's lead candidate, IM1240, is advancing toward the clinic, and its second candidate, IM1305, is in preclinical development. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue", "potential", "designed to" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for CAPTN-3; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; our ability to raise additional capital on acceptable terms, or at all, to fund our research and development activities, including preclinical and clinical studies; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2025 as such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.

CONTACTS:

Company Contact:
IR@purple-biotech.com


 

Purple Biotech Ltd.

 

Condensed Consolidated Unaudited Interim Statements of Financial Position

 

 

 

 

 

September 30,

 

 

December 31,

 

 

 

 

 

2026

 

 

2025

 

 

 

 

 

USD thousand

 

 

USD thousand

 

Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

 

4,270

 

 

 

8,717

 

Short term deposits

 

 

 

 

865

 

 

 

857

 

Other current assets

 

 

 

 

281

 

 

 

292

 

 

 

 

 

 

 

 

 

 

 

 

Total current assets

 

 

 

 

5,416

 

 

 

9,866

 

Non-current assets

 

 

 

 

 

 

 

 

 

 

Right of use assets

 

 

 

 

38

 

 

 

222

 

Fixed assets, net

 

 

 

 

115

 

 

 

124

 

Intangible assets

 

 

 

 

7,360

 

 

 

7,360

 

 

 

 

 

 

 

 

 

 

 

 

Total non-current assets

 

 

 

 

7,513

 

 

 

7,706

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

 

 

12,929

 

 

 

17,572

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

Lease liability

 

 

 

 

66

 

 

 

244

 

Trade payables

 

 

 

 

621

 

 

 

2,070

 

Warrants

 

 

 

 

61

 

 

 

4,066

 

Other payables

 

 

 

 

783

 

 

 

1,373

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

 

 

 

1,531

 

 

 

7,753

 

 

 

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

 

 

Post-employment benefit liabilities

 

 

 

 

166

 

 

 

160

 

 

 

 

 

 

 

 

 

 

 

 

Total non-current liabilities

 

 

 

 

166

 

 

 

160

 

Equity

 

 

 

 

 

 

 

 

 

 

Share capital, no par value

 

 

 

 

-

 

 

 

-

 

Share premium

 

 

 

 

155,813

 

 

 

152,483

 

Receipts on account of warrants

 

 

 

 

21,145

 

 

 

21,145

 

Capital reserve for share-based payments

 

 

 

 

6,135

 

 

 

7,263

 

Capital reserve from transactions with related parties

 

 

 

 

761

 

 

 

761

 

Capital reserve from transactions with non-controlling interest

 

 

 

 

(859)

 

 

 

(859)

 

Accumulated loss

 

 

 

 

(171,705)

 

 

 

(171,079)

 

 

 

 

 

 

 

 

 

 

 

 

Equity attributable to owners of the Company

 

 

 

 

11,290

 

 

 

9,714

 

Non-controlling interests

 

 

 

 

(58)

 

 

 

(55)

 

 

 

 

 

 

 

 

 

 

 

 

Total equity

 

 

 

 

11,232

 

 

 

9,659

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities and equity

 

 

 

 

12,929

 

 

 

17,572

 

 

 

 

 

 

 

 

 

Purple Biotech Ltd.

 

Condensed Consolidated Unaudited Interim Statements of Operations and Other Comprehensive Income

 

 

 

 

For the nine months ended
September 30,

 

 

For the three months ended
September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

USD thousand

 

 

USD thousand

 

 

USD thousand

 

 

USD thousand

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

2,297

 

 

 

1,903

 

 

 

364

 

 

 

587

 

General and administrative expenses

 

 

2,353

 

 

 

2,110

 

 

 

735

 

 

 

780

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

4,650

 

 

 

4,013

 

 

 

1,099

 

 

 

1,367

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrants

 

 

(4,012)

 

 

 

(951)

 

 

 

(168)

 

 

 

56

 

Finance expense

 

 

28

 

 

 

16

 

 

 

66

 

 

 

5

 

Finance income

 

 

(37)

 

 

 

(228)

 

 

 

(16)

 

 

 

(123)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finance income, net

 

 

(4,021)

 

 

 

(1,163)

 

 

 

(118)

 

 

 

(62)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss for the period

 

 

629

 

 

 

2,850

 

 

 

981

 

 

 

1,305

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total loss for the period

 

 

629

 

 

 

2,850

 

 

 

981

 

 

 

1,305

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss attributable to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Owners of the Company

 

 

626

 

 

 

2,841

 

 

 

981

 

 

 

1,303

 

Non-controlling interests

 

 

3

 

 

 

9

 

 

 

-

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

629

 

 

 

2,850

 

 

 

981

 

 

 

1,305

 

Loss per share information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per Share – USD

 

 

0.00026

 

 

 

0.004

 

 

 

0.0003

 

 

 

0.001

 

Number of Shares used in calculation

 

 

2,435,316,772

 

 

 

662,986,963

 

 

 

3,257,071,391

 

 

 

911,039,091

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per ADS information (where 1 ADS represents 2000 shares)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per ADS – USD

 

 

0.51

 

 

 

*8.60

 

 

 

0.6

 

 

 

*2.86

 

 Number of ADSs used in calculation

 

 

1,217,658

 

 

 

*331,493

 

 

 

1,628,536

 

 

 

*455,520

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*

Restated to reflect the change in the ADS ratio from 1:200 to 1:2,000, effective March 2026.

 

 

 

 

 

 

 

 

 

 

 

 

 

Purple Biotech Ltd.

 

Reconciliation of IFRS to Non-IFRS Financial Measures (Unaudited)

 

 

Reconciliation of Adjusted Operating Loss

 

 

 

For the nine months ended
September 30,

 

 

For the three months ended
September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

USD
thousand

 

 

USD
thousand

 

 

USD
thousand

 

 

USD
thousand

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss for the period

 

 

4,650

 

 

 

4,013

 

 

 

1,099

 

 

 

1,367

 

Less ESOP expenses

 

 

(210)

 

 

 

(203)

 

 

 

(50)

 

 

 

(51)

 

 

 

 

4,440

 

 

 

3,810

 

 

 

1,049

 

 

 

1,316

 

 

 

Reconciliation of Adjusted Net Loss

 

 

For the nine months ended
September 30,

 

 

For the three months ended
September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

USD
thousand

 

 

USD
thousand

 

 

USD
thousand

 

 

USD
thousand

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss for the period

 

 

629

 

 

 

2,850

 

 

 

981

 

 

 

1,305

Less ESOP expenses

 

 

(210)

 

 

 

(203)

 

 

 

(50)

 

 

 

(51)

Change in fair value of warrants

 

 

4,012

 

 

 

951

 

 

 

168

 

 

 

(56)

 

 

 

4,431

 

 

 

3,598

 

 

 

1,099

 

 

 

1,198

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purple Biotech Ltd.

 

Condensed Consolidated Unaudited Interim Statements of Cash Flows

 

 

 

 

 

 

For the nine months ended
September 30,

 

 

 

 

 

2026

 

 

2025

 

 

 

 

 

USD thousand

 

 

USD thousand

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Loss for the period

 

 

 

 

(629)

 

 

 

(2,850)

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

 

 

200

 

 

 

150

 

Finance income, net

 

 

 

 

(4,021)

 

 

 

(1,163)

 

Share-based payments

 

 

 

 

210

 

 

 

352

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,240)

 

 

 

(3,511)

 

 

 

 

 

 

 

 

 

 

 

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

 

 

Changes in other investments and other current assets

 

 

 

 

(11)

 

 

 

(135)

 

Changes in accounts payables

 

 

 

 

(1,615)

 

 

 

(843)

 

Changes in other payables

 

 

 

 

(551)

 

 

 

(100)

 

 

 

 

 

 

(2,177)

 

 

 

(1,078)

 

 

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

 

 

 

(6,417)

 

 

 

(4,589)

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

Proceeds from other investments

 

 

 

 

-

 

 

 

610

 

Interest received

 

 

 

 

77

 

 

 

134

 

Increase in short-term deposits

 

 

 

 

(8)

 

 

 

(14)

 

Disposals (Acquisition) of fixed assets

 

 

 

 

(7)

 

 

 

6

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by investing activities

 

 

 

 

62

 

 

 

736

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of ADSs

 

 

 

 

2,300

 

 

 

2,895

 

ADS issuance expenses paid

 

 

 

 

(161)

 

 

 

(387)

 

Proceeds from issuance of warrants

 

 

 

 

-

 

 

 

4,240

 

Warrants issuance expenses paid

 

 

 

 

-

 

 

 

(547)

 

Repayment of lease liability

 

 

 

 

(191)

 

 

 

(156)

 

Interest paid

 

 

 

 

(10)

 

 

 

(9)

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by financing activities

 

 

 

 

1,938

 

 

 

6,036

 

 

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

 

 

(4,417)

 

 

 

2,183

 

Cash and cash equivalents at the beginning of the period

 

 

 

 

8,717

 

 

 

7,401

 

Effect of translation adjustments on cash and cash equivalents

 

 

 

 

(30)

 

 

 

8

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at the end of the period

 

 

 

 

4,270

 

 

 

9,592

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading